Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab (Xolair) for severe chronic urticaria not responding to antihistamines
2010-024113-31Phase 2Completed
- Sponsor
- Cima Universidad de Navarra
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in chronic urticaria (CU) (2 arms), sponsored by Cima Universidad de Navarra. Primary endpoint: Diagnostic/efficacy endpoint. Started Feb 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on 2010-024113-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024113-31.